ABION Inc. (203400.KQ) News
Track canonical SquawkNews coverage tagged to 203400.KQ, ABION Inc.. This hub brings together deduplicated headlines about kosdaq, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 2 indexed stories across 1 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Korea Exchange flags Abion for KOSDAQ delisting review; decision due by Oct. 30, 2026
Korea Exchange has designated Abion for a substantive listing eligibility review under KOSDAQ rules, targeting a decision within 20 business days by Oct. 30, 2026. A management improvement plan filed by Oct. 23 would res
EQUITY | Sep 30, 2026, 10:43 AM UTC
M
Abion signs iADC joint research and licensing deal with LigaChem Biosciences
Abion entered a joint research and licensing deal with LigaChem Biosciences to co-develop an iADC drug candidate, using Abion’s IFN-β mutein immunocytokine-antibody and LigaChem’s proprietary ADC platform; LigaChem has e
EQUITY | Sep 30, 2026, 08:05 AM UTC